Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort
Lauren Folgosa Cooley(Virginia Commonwealth University), William J. Catàlona(Northwestern University), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Travis J. Meyers(University of California, Los Angeles), Denise Scholtens(Northwestern University), Adaeze A. Emeka(Northwestern University), Todd M. Morgan(University of Michigan), Stacy Loeb(Manhattan Physical Medicine and Rehabilitation), John S. Witte(University of California, San Francisco), Phillip R. Cooper(Northwestern University), Daniel A. Barocas(Vanderbilt University Medical Center), Christian P. Pavlovich(Johns Hopkins University), Daniel W. Lin(University of Washington), S. Larry Goldenberg(University of British Columbia), Danny Vesprini(Sunnybrook Health Science Centre), June M. Chan(University of California, San Francisco), Antonio Finelli(University Health Network), Leonard S. Marks(Urological Research Foundation), Brian T. Helfand(NorthShore University HealthSystem), Eric A. Klein(Meta (United States)), James A. Eastham(Memorial Sloan Kettering Cancer Center), Celestia S. Higano(University of British Columbia)
Cited by 28
Related Papers
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
|Diabetes Care|1994|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k